Targeting the Androgen Receptor Pathway in Prostate Cancer: A PROTrACted Struggle
The androgen receptor (AR) is the most important therapeutic target for metastatic prostate cancer. Though clinical responses to AR inhibition are nearly universal, so is progression, usually accompanied by reactivation of AR signaling. A new small-molecule dual AR degrader/inhibitor shows promise in overcoming resistance and improving clinical outcomes. See related article by Nayak et al., p. 224.
Authors
- Peter S. Nelson (ORCID: https://orcid.org/0000-0002-5451-5726)
- Michael D. Nyquist (ORCID: https://orcid.org/0009-0003-9531-3658)
Institutions
- Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa (ZA)
- Fred Hutch Cancer Center (US)
Publication Details
- Journal
- Clinical Cancer Research
- Published
- 2025-10-29
- DOI
- https://doi.org/10.1158/1078-0432.ccr-25-3045
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00